Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Taiwan Advanced Nanotech's Debt-to-EBITDA or its related term are showing as below:
ROCO:6797'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.3 Med: -1.81 Max: 0.75
Current: -2.52
During the past 9 years, the highest Debt-to-EBITDA Ratio of Taiwan Advanced Nanotech was 0.75. The lowest was -4.30. And the median was -1.81.
ROCO:6797's Debt-to-EBITDA is ranked worse than 100% of 478
companies
in the Medical Devices & Instruments industry
Industry Median: 1.65
vs ROCO:6797: -2.52
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Taiwan Advanced Nanotech Debt-to-EBITDA Related Terms
Taiwan Advanced Nanotech Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6797 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Taiwan Advanced Nanotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Advanced Nanotech Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Taiwan Advanced Nanotech's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Taiwan Advanced Nanotech's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Taiwan Advanced Nanotech (ROCO:6797) has a Debt-to-EBITDA of -2.29 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Taiwan Advanced Nanotech. According to the industry distribution chart, Taiwan Advanced Nanotech ranks #999999 out of 478 companies in the Medical Devices & Instruments industry.
Is Taiwan Advanced Nanotech's Debt-to-EBITDA too high?
Taiwan Advanced Nanotech's current Debt-to-EBITDA is -2.29. Based on the distribution chart, Taiwan Advanced Nanotech ranks #999999 out of 478 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Taiwan Advanced Nanotech has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advanced Nanotech's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Taiwan Advanced Nanotech ranks #999999 out of 478 companies for Debt-to-EBITDA. This places Taiwan Advanced Nanotech in the lower half of its industry. The industry median Debt-to-EBITDA is 1.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.65, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Taiwan Advanced Nanotech. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Advanced Nanotech's current Debt-to-EBITDA is -2.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advanced Nanotech stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advanced Nanotech (ROCO:6797) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$16.43, compared to a current price of NT$12.00 — trading 27% below its estimated fair value. The current Debt-to-EBITDA is -2.29. Taiwan Advanced Nanotech's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Taiwan Advanced Nanotech (ROCO:6797), the current Debt-to-EBITDA is -2.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Advanced Nanotech (ROCO:6797) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Advanced Nanotech stock appears to be undervalued.
The current stock price of NT$12.00 is trading 27% below its estimated GF Value™ of NT$16.43.
GuruFocus considers Taiwan Advanced Nanotech to be Modestly Undervalued.
Key valuation signals for ROCO:6797:
Debt-to-EBITDA: -2.29
GF Value™: NT$16.43 vs. price of NT$12.00 (27% below fair value)
No single metric tells the full story. See the ROCO:6797 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Advanced Nanotech Inc is engaged in development and manufacturing of various functional nanoparticles and automated nucleic acid extraction machines and trading related businesses. With expertise in automation, buffer optimization and modification of magnetic beads, it focuses on offering customer convenient and practical solutions to advance research, life science and molecular diagnostics. It offers various products to meet the requirements of customers. The company's products include Automated Extraction Instruments; Reagent Kit; Mag Nanoparticles; and Consumables.
60GF Score
Get the complete analysis for ROCO:6797
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6797 has been successfully added to your 
